for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Prothena Corporation PLC

PRTA.OQ

Latest Trade

11.29USD

Change

0.11(+0.98%)

Volume

37,203

Today's Range

11.09

 - 

11.35

52 Week Range

7.10

 - 

17.54

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.18
Open
11.23
Volume
37,203
3M AVG Volume
5.63
Today's High
11.35
Today's Low
11.09
52 Week High
17.54
52 Week Low
7.10
Shares Out (MIL)
39.92
Market Cap (MIL)
450.71
Forward P/E
-4.15
Dividend (Yield %)
--

Next Event

Q4 2020 Prothena Corporation PLC Earnings Release

Latest Developments

More

Prothena Reports Third Quarter 2020 Financial Results And Provides Research And Development Update

Roche And Prothena Will Advance Prasinezumab Into Late-Stage Clinical Development Study In Parkinson’S Disease

Prothena Corporation PLC Says Prasinezumab Slows Progression On Measures Of Parkinson's Disease In Phase 2 Study

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Prothena Corporation PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Industry

Biotechnology & Drugs

Contact Info

Dublin 1, 25-28 North Wall Quay

A96 T927

Ireland

+353.1.2362500

http://www.prothena.com/

Executive Leadership

Lars G. Ekman

Independent Chairman of the Board

Gene G. Kinney

President, Chief Executive Officer, Director

Tran B. Nguyen

Chief Financial Officer, Chief Operating Officer

Karin L. Walker

Chief Accounting Officer, Controller

Wagner M. Zago

Chief Scientific Officer

Key Stats

2.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-4.070

2018

-3.930

2019

-1.950

2020(E)

-2.736
Price To Earnings (TTM)
--
Price To Sales (TTM)
601.75
Price To Book (MRQ)
2.15
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-27.08
Return on Equity (TTM)
-25.28

Latest News

Latest News

U.S. RESEARCH ROUNDUP-Ashland Global, Lyft, Solaredge Technologies

Wall Street securities analysts on Thursday revised their ratings and price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and Solaredge Technologies. HIGHLIGHTS * Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight...

BRIEF-Prothena Corporation Plc- Update On Prasinezumab Expected Later This Year

* UPDATE ON PHASE 2 PASADENA STUDY OF PRASINEZUMAB (PRX002/RG7935) IN PARKINSON’S DISEASE

BRIEF-Baseline Data From Phase 2 Pasadena Study Of Prasinezumab In Parkinson's Disease To Be Presented At AAT-AD/PD

* BASELINE DATA FROM PHASE 2 PASADENA STUDY OF PRASINEZUMAB (PRX002/RG7935) IN PARKINSON’S DISEASE TO BE PRESENTED AT AAT-AD/PD Source text for Eikon: Further company coverage:

Ocado nabs spot in FTSE 100 as traditional retailers shrink

* Retailers Mothercare and Moss Bros drop out of FTSE All-Share

BRIEF-Prothena Reports Q1 Loss Per Share $1.26

* PROTHENA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES RESEARCH AND DEVELOPMENT UPDATE

BRIEF-Prothena Corp Reports Q1 Loss Per Share $1.26

* PROTHENA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES RESEARCH AND DEVELOPMENT UPDATE

PRESS DIGEST- British Business - April 24

The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.

Woodford-backed biotech Prothena plunges as key drug fails

Shares in Prothena, a biotech company backed by British investor Neil Woodford, plunged 70 percent on Monday after its main drug for treating a rare disease called AL amyloidosis failed in a crucial clinical trial.

BRIEF-Woodford Investment Says Will Be Working With Prothena Corp On Its Strategy Beyond Its Pronto Trial Investigating NEOd001 In Al Amyloidosis

* WOODFORD INVESTMENT MANAGEMENT SAYS WILL BE WORKING WITH PROTHENA CORP ON ITS STRATEGY BEYOND ITS PRONTO TRIAL INVESTIGATING NEOD001 IN AL AMYLOIDOSIS Source text: (http://bit.ly/2HRH9mk) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Prothena Discontinues Development Of NEOD001 For Al Amyloidosis

* PROTHENA DISCONTINUES DEVELOPMENT OF NEOD001 FOR AL AMYLOIDOSIS

BRIEF-Prothena Announces Global Neuroscience Research & Development Collaboration With Celgene

* PROTHENA ANNOUNCES GLOBAL NEUROSCIENCE RESEARCH & DEVELOPMENT COLLABORATION WITH CELGENE FOR NOVEL THERAPIES FOR PATIENTS WITH NEURODEGENERATIVE DISEASES

BRIEF-Prothena Corp Files For Potential Stock Shelf Offering

* PROTHENA CORPORATION PLC FILES FOR POTENTIAL STOCK SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2oyv9Nv) Further company coverage:

BRIEF-Prothena Q4 Loss Per Share $1.24

* PROTHENA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS, AND PROVIDES FINANCIAL GUIDANCE AND RESEARCH AND DEVELOPMENT UPDATE

BRIEF-Prothena Q4 Loss Per Share $1.24

* PROTHENA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS, AND PROVIDES FINANCIAL GUIDANCE AND RESEARCH AND DEVELOPMENT UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up